Triamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)

Covered only for a single 32 mg intra‑articular injection of Zilretta for FDA‑approved knee osteoarthritis; non‑FDA uses, other joints, and prior receipt of Zilretta are excluded. Approval requires the patient be Zilretta‑naïve with documented knee OA, inadequate response/intolerance/contraindication to ≥2 of acetaminophen, NSAIDs, or tramadol, prior inadequate response to an intra‑articular corticosteroid, and meeting applicable safety/documentation requirements.

"Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee."

Sign up to see full coverage criteria, indications, and limitations.